British pharmaceutical firm GlaxoSmithKline (GSK) has pledged an investment of $30 billion in its U.S. operations over the next five years, reports BBC News.

GSK said in a statement that $1.2 billion would be used to build a new factory in Pennsylvania to develop medicines for respiratory diseases and cancer. Construction is planned to start in 2026.

The money will also fund new AI and digital technology tools across GSK's five American manufacturing sites, including those in North Carolina and Maryland.

The rest of the $30 billion investment will support GSK's supply chain and drug research efforts, the company said.

The announcement came at the start of U.S. President Donald Trump's visit to the U.K., as drugmakers face pressure from the Trump administration to move production to the U.S., threatening tariffs as steep as 250% on pharmaceutical imports.

Read More: European Pharma Giants Threaten ‘Exodus’ to the U.S.

British Prime Minister Sir Keir Starmer said the investment was a "powerful example" of collaboration between the countries and would create new jobs and boost drug development.

GSK’s CEO, Emma Walmsley, said the pharma giant plans to keep investing in its U.K. manufacturing base and will continue spending over £1.5 billion ($2 billion) yearly on research and development in the country.